Institute of Cardiovascular and Metabolic Diseases (I2MC - UMR1048)

The new Institute of Cardiovascular and Metabolic Diseases (I2MC) was created in Toulouse on January 1, 2011 by Inserm and Paul Sabatier University.


More than 280 people (scientists, physicians, engineers, technicians, students, postdocs and administrators) are working at I2MC

The research activity focuses on metabolic, cardiovascular and renal diseases. The main feature of I2MC is the gathering of basic scientists together with clinicians working on metabolic risk factors (obesity, diabetes and dyslipidemia) and their cardiovascular complications (thrombosis, atherosclerosis, cardiac and renal failure).

schema accueil v5

I2MC is composed of 14 research teams. The teams share a similar "research philosophy" consisting in multidisciplinary approaches from basic science to clinical trials. In terms of basic research, the laboratories have a large expertise in membrane and intracellular receptors, cell signaling, metabolic pathways, cell/cell interactions and the mechanisms of tissue remodeling. To establish the pathophysiological relevance of the results obtained in basic research, I2MC teams have created original animal models and phenotyping techniques that have gained national recognition and are one of the highlights of the Institute. Translation to the clinic is greatly facilitated by the location within the Rangueil site of Toulouse University Hospitals. Notably, clinical departments devoted to nutrition, cardiovascular and renal diseases, obesity and diabetes are in close vicinity of I2MC. It helps the involvement of a large number of MD-PhD to the scientific activity of the laboratories. More than 25 clinical research protocols coming from original research obtained by I2MC teams have been performed during the last three years.

The industrial valorization of the research is another strength of I2MC. Numerous structured collaborations are ongoing with industrial partners, from SMEs to big pharmas. I2MC research directly contributed to the creation of 4 start up companies.



Latest publications

Galanin enhances systemic glucose metabolism through enteric Nitric Oxide Synthase-expressed neurons (team 3)

PMID : 29428595 | Revue : Mol. Metab.

Auteurs : A. ABBOT, et al.

Regulation of glucose metabolism by bioactive phytochemicals for the management of type 2 diabetes mellitus (team 1)

PMID : 30501400 | Revue : Crit Rev Food Sci Nutr

Auteurs : Zhao C, Yang C, Wai STC, Zhang Y, P Portillo M, Paoli P, Wu Y, San Cheang W, Liu B, Carpén...

Impact of PI3Kα (Phosphoinositide 3-Kinase Alpha) Inhibition on Hemostasis and Thrombosis. (team 11)

PMID : 30354258 | Revue : Arterioscler Thromb Vasc Biol.

Auteurs : Laurent PA, Hechler B, Solinhac R, Ragab A, Cabou C, Anquetil T, Severin S, Denis CV, Mangin PH, ...

Job offers

  • [CDD - 30 mois] IE Technique

    (team 2)

    Ingénieur d'étude (H/F) - Microbiote intestinal et maladie d'Alzheimer à Montpellier (UMR5203-SYLCLA-001)

  • [CDD] Post-Doctorant

    (team 13)

    3 years position
    "Identify therapeutic target for lymphedema"

  • [CDD] IE

    (team 13)

    2 years postition.
    Gene therapy for lymphedema